<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://feeds2.feedburner.com/AmericanBankingNews</forum>
<forum_title>American Banking News</forum_title>
<discussion_title>Valeant Pharmaceuticals Intl Inc (VRX) Receives Sell Rating from Wells Fargo</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.americanbankingnews.com/2016/04/25/valeant-pharmaceuticals-intl-inc-vrx-receives-sell-rating-from-wells-fargo/</topic_url>
<topic_text>
Tweet 
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ‘s stock had its “sell” rating reaffirmed by research analysts at Wells Fargo in a research report issued on Monday, MarketBeat Ratings reports. 
Several hedge funds and institutional investors have modified their holdings of the company. Janus Capital Management boosted its position in shares of Valeant Pharmaceuticals Intl by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares during the period. Korea Investment CORP boosted its position in shares of Valeant Pharmaceuticals Intl by 178.4% in the fourth quarter. Korea Investment CORP now owns 238,600 shares of the specialty pharmaceutical company’s stock worth $24,143,000 after buying an additional 152,900 shares during the period. Stoneridge Investment Partners LLC acquired a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth $7,599,000. Russell Frank Co boosted its position in shares of Valeant Pharmaceuticals Intl by 119.4% in the fourth quarter. Russell Frank Co now owns 289,002 shares of the specialty pharmaceutical company’s stock worth $29,575,000 after buying an additional 157,307 shares during the period. Finally, Iridian Asset Management LLC CT boosted its position in shares of Valeant Pharmaceuticals Intl by 59.2% in the fourth quarter. Iridian Asset Management LLC CT now owns 4,324,602 shares of the specialty pharmaceutical company’s stock worth $439,596,000 after buying an additional 1,607,834 shares during the period. 
Several other research analysts also recently commented on the company. Mizuho restated a “neutral” rating and set a $112.00 price objective (down from $130.00) on shares of Valeant Pharmaceuticals Intl in a report on Sunday, January 3rd. Barclays downgraded Valeant Pharmaceuticals Intl from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $135.00 to $34.00 in a report on Monday, March 21st. Vetr upgraded Valeant Pharmaceuticals Intl from a “buy” rating to a “strong-buy” rating and set a $122.73 price target on the stock in a report on Tuesday, December 29th. TD Securities downgraded Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating and cut their price target for the company from $155.00 to $110.00 in a report on Monday, February 29th. Finally, Jefferies Group reiterated a “buy” rating and issued a $106.00 price target (down from $172.00) on shares of Valeant Pharmaceuticals Intl in a report on Monday, February 29th. Seven research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $90.44. 
Shares of Valeant Pharmaceuticals Intl ( NYSE:VRX ) traded down 0.9175% during trading on Monday, hitting $35.6499. The company had a trading volume of 27,697,664 shares. The firm has a market capitalization of $12.23 billion and a P/E ratio of 20.4767. Valeant Pharmaceuticals Intl has a 1-year low of $25.27 and a 1-year high of $263.81. The company’s 50 day moving average is $38.25 and its 200 day moving average is $84.82. 
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $2.50 EPS for the quarter, missing the consensus estimate of $2.61 by $0.11. The business earned $2.80 billion during the quarter, compared to the consensus estimate of $2.75 billion. The firm’s revenue for the quarter was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 EPS. Analysts anticipate that Valeant Pharmaceuticals Intl will post $8.79 earnings per share for the current fiscal year. 
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter ( NYSE:VRX ) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.  //www.americanbankingnews.com/2016/04/25/valeant-pharmaceuticals-intl-inc-vrx-receives-sell-rating-from-wells-fargo/   Valeant Pharmaceuticals Intl Inc   Valeant Pharmaceuticals Intl Inc  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.americanbankingnews.com/2016/04/25/valeant-pharmaceuticals-intl-inc-vrx-receives-sell-rating-from-wells-fargo/</post_url>
<post_date>20160425</post_date>
<post_time>1839</post_time>
<username>ABMN Staff</username>
<post>
Tweet 
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ‘s stock had its “sell” rating reaffirmed by research analysts at Wells Fargo in a research report issued on Monday, MarketBeat Ratings reports. 
Several hedge funds and institutional investors have modified their holdings of the company. Janus Capital Management boosted its position in shares of Valeant Pharmaceuticals Intl by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares during the period. Korea Investment CORP boosted its position in shares of Valeant Pharmaceuticals Intl by 178.4% in the fourth quarter. Korea Investment CORP now owns 238,600 shares of the specialty pharmaceutical company’s stock worth $24,143,000 after buying an additional 152,900 shares during the period. Stoneridge Investment Partners LLC acquired a new position in shares of Valeant Pharmaceuticals Intl during the fourth quarter worth $7,599,000. Russell Frank Co boosted its position in shares of Valeant Pharmaceuticals Intl by 119.4% in the fourth quarter. Russell Frank Co now owns 289,002 shares of the specialty pharmaceutical company’s stock worth $29,575,000 after buying an additional 157,307 shares during the period. Finally, Iridian Asset Management LLC CT boosted its position in shares of Valeant Pharmaceuticals Intl by 59.2% in the fourth quarter. Iridian Asset Management LLC CT now owns 4,324,602 shares of the specialty pharmaceutical company’s stock worth $439,596,000 after buying an additional 1,607,834 shares during the period. 
Several other research analysts also recently commented on the company. Mizuho restated a “neutral” rating and set a $112.00 price objective (down from $130.00) on shares of Valeant Pharmaceuticals Intl in a report on Sunday, January 3rd. Barclays downgraded Valeant Pharmaceuticals Intl from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $135.00 to $34.00 in a report on Monday, March 21st. Vetr upgraded Valeant Pharmaceuticals Intl from a “buy” rating to a “strong-buy” rating and set a $122.73 price target on the stock in a report on Tuesday, December 29th. TD Securities downgraded Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating and cut their price target for the company from $155.00 to $110.00 in a report on Monday, February 29th. Finally, Jefferies Group reiterated a “buy” rating and issued a $106.00 price target (down from $172.00) on shares of Valeant Pharmaceuticals Intl in a report on Monday, February 29th. Seven research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $90.44. 
Shares of Valeant Pharmaceuticals Intl ( NYSE:VRX ) traded down 0.9175% during trading on Monday, hitting $35.6499. The company had a trading volume of 27,697,664 shares. The firm has a market capitalization of $12.23 billion and a P/E ratio of 20.4767. Valeant Pharmaceuticals Intl has a 1-year low of $25.27 and a 1-year high of $263.81. The company’s 50 day moving average is $38.25 and its 200 day moving average is $84.82. 
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its quarterly earnings data on Tuesday, March 15th. The specialty pharmaceutical company reported $2.50 EPS for the quarter, missing the consensus estimate of $2.61 by $0.11. The business earned $2.80 billion during the quarter, compared to the consensus estimate of $2.75 billion. The firm’s revenue for the quarter was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 EPS. Analysts anticipate that Valeant Pharmaceuticals Intl will post $8.79 earnings per share for the current fiscal year. 
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter ( NYSE:VRX ) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.  //www.americanbankingnews.com/2016/04/25/valeant-pharmaceuticals-intl-inc-vrx-receives-sell-rating-from-wells-fargo/   Valeant Pharmaceuticals Intl Inc   Valeant Pharmaceuticals Intl Inc  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.americanbankingnews.com/logos/valeant-pharmaceuticals-logo.gif</main_image>
</document>
